HANCOCK DANIEL M
Known title: DirectorCIK: 0001764017
Associated companies
Transaction History
| CYRX | ▲ Buy | Grant | 10,350 | $0 | 6/5/2026 | View on chart |
| CYRX | ▲ Buy | Grant | 23,214 | $0 | 6/6/2025 | View on chart |
| CYRX | ▲ Buy | Grant | 12,845 | $0 | 5/17/2024 | View on chart |
| CYRX | ▲ Buy | Grant | 8,105 | $0 | 5/12/2023 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 2,708 | — | 4/30/2022 | View on chart |
| CYRX | ▲ Buy | Grant | 7,203 | $0 | 4/29/2022 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 11,217 | $161K | 10/21/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 5,900 | $444K | 10/21/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 5,317 | $405K | 10/21/2021 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 3,783 | $54K | 10/20/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 3,783 | $284K | 10/20/2021 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 10,000 | $144K | 9/27/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 10,000 | $702K | 9/27/2021 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 574 | $8K | 9/2/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 574 | $39K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CryoPort Q2 Earnings and BTIG Price Target Hike
CryoPort recently released its Q2 2026 earnings call transcript, providing insight into its recent performance. Following this, BTIG maintained a positive stance on the stock and raised its price target to $26. This update sits at the top of the current analyst range, which spans from $15.00 to $26.00, reflecting increased confidence in the company's outlook.
CryoPort Q2 Earnings and BTIG Price Target Hike. CryoPort recently released its Q2 2026 earnings call transcript, providing insight into its recent performance. Following this, BTIG maintained a positive stance on the stock and raised its price target to $26. This update sits at the top of the current analyst range, which spans from $15.00 to $26.00, reflecting increased confidence in the company's outlook.